News | PET Imaging | January 25, 2017

New PET Imaging Technique May Help Monitor Neurological Disease Progression

Researchers use radiotracer that binds to mature olfactory sensory neurons to quantify neuronal populations

January 25, 2017 — In work published this week in the Journal of Clinical Investigation (JCI), a team led by Jacob Hooker at Harvard Medical School assessed GV1-57, a radiotracer that specifically binds to mature olfactory sensory neurons, as an approach for quantifying neuronal populations with positron emission tomography (PET) imaging.

Olfactory neurons in the nasal cavity are the primary source of our sense of smell. Unlike many types of neurons, olfactory neurons are continuously generated throughout the adult lifespan. This uniquely high rate of neuronal birth and death makes olfactory neurons particularly sensitive to the detrimental effects of progressive neurodevelopmental and neurodegenerative disease. In Alzheimer's disease and Parkinson's disease, loss of the sense of smell often precedes classical symptoms of cognitive or motor dysfunction. Therefore, a technique that is able to non-invasively quantify the olfactory neuron population could provide important insights related to the diagnosis and progression of neurodevelopmental and neurodegenerative diseases.

Using GV1-57, researchers were able to detect neuron generation during rodent postnatal development as well as neuron degeneration in rodent models of aging and neurodegenerative disease. In an additional proof-of-concept experiment, they showed that GV1-57 maintained saturable binding in non-human primate nasal cavity, suggesting that this radiotracer may be useful for evaluating neurological disease in clinical settings.

For more information: www.jci.org

Van de Bittner, G.C., Riley, M.M., Cao, L., Ehses, J., et al. "Nasal neuron PET imaging quantifies neuron generation and degeneration," The Journal of Clinical Invesigation. Published Jan. 23, 2017. doi:10.1172/JCI89162

Related Content

GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MaxQ AI Receives FDA Clearance for Accipio Ix Intracranial Hemorrhage Platform
Technology | Artificial Intelligence | November 07, 2018
MaxQ AI announced that its Accipio Ix intracranial hemorrhage (ICH) detection software has received 510(k) clearance...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
Feature | PET Imaging | November 07, 2018 | By Greg Freiherr
Positron emission tomography (PET) is getting ready to venture outside oncology, cardiology and mainstream neurology....
Podcast | PET Imaging | November 07, 2018
PET is getting ready to venture outside oncology, cardiology and mainstream neurology.
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages